Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
Authors:
Open Access
- 5 December 2014
- journal article
- research article
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 8 (3) , 283-291
Abstract
Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as demonstrated by an increase in walking speed. On-drug patient perspectives and experiences are valuable to understand and manage this patient population.Keywords
This publication has 22 references indexed in Scilit:
- Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort studyMultiple Sclerosis Journal, 2013
- Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 casesPatient Related Outcome Measures, 2013
- Impact of Walking Impairment in Multiple SclerosisThe Patient - Patient-Centered Outcomes Research, 2011
- Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practiceTherapeutic Advances in Neurological Disorders, 2011
- Symptomatic Management in Multiple SclerosisNeurologic Clinics, 2011
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnnals of Neurology, 2010
- Identification, causation, alleviation, and prevention of complications (ICAP)Neurology, 2008
- Patient perceptions of insulin detemir as reported through patient telephone surveysCurrent Medical Research and Opinion, 2007
- The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis siccaCurrent Medical Research and Opinion, 2005
- The measurement of disabilityInternational Clinical Psychopharmacology, 1996